国际医疗器械设计与制造技术展览会

Dedicated to design & manufacturing for medical device

September 25-27,2024 | SWEECC H1&H2

EN | 中文
   

Policies & Regulations

  • 2024.07.19

    How to Navigate FDA’s Medical Device Cybersecurity Recommendations

    FDA is cracking down on medical device cybersecurity. In response to an increase in healthcare cybersecurity threats, prevalence of connected devices, and pressure from the United States Government Accountability Office (GAO), the agency issued final guidance on medical device quality system and premarket submission requirements. In March, FDA released an update to clarify what devices must comply, as well as to give more specifics on the proposed cybersecurity plan.


    Read More
  • 2024.07.18

    EU MDR Poses Challenges for Manufacturers

    To provide an overview of EU MDR, we turned to Abhishek (Abhi) Gautam, MS, EMBA, who is an executive engineer at DDL Inc., an ISO/IEC 17025 accredited full-service testing lab that provides package, product, and materials testing to the medical device and pharmaceutical industries, headquartered in Eden Prairie, Minnesota.


    Read More
  • 2024.06.06

    FDA under fire: Pared-down LDT Final Rule leaves unanswered questions

    The U.S. Food and Drug Administration (FDA) has finalized its historic — and notoriously controversial — rule to explicitly assert the agency’s authority to regulate laboratory developed tests (LDTs).


    Read More
  • 2024.06.04

    Quality Management System Regulation: Final Rule Amending the Quality System Regulation – Frequently Asked Questions

    In the Quality Management System Regulation final rule issued today, the FDA is amending the title of the regulation, and establishing requirements and provisions that clarify certain expectations and concepts used in ISO 13485:2016. The revised part 820 is referred to as the Quality Management System Regulation (QMSR).


    Read More
  • 2024.05.24

    FDA Outlines its Approach to Artificial Intelligence Regulation

    U.S. regulation of artificial intelligence (AI) in medical devices will involve cooperative work among multiple departments within the FDA. On March 15, the FDA released “Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” which outlines how the agency’s medical product centers plan to address the efforts required to protect public health while fostering responsible innovation in AI used in medical products and their development.


    Read More
  • 2024.05.20

    Ensuring Continued Availability of In-Vitro Diagnostics in UK, EU


    Read More
  • 2024.03.11

    Getting to Yes From FDA

    As the co-founder and CEO of FastWave Medical and the founder of Medsider, I’ve spoken to entrepreneurs who have found the regulatory journey to be more collaborative than confrontational.


    Read More
  • 2024.01.17

    ISO 80369-7: Changing the Standard for Luer Connectors

    ISO 80369 Part 7, the long-awaited replacement to ISO 594, introduced a number of changes to the standard governing dimensions and performance requirements of Luer connectors. Its publication in October 2016 capped a monumental change in the fundamental thinking surrounding devices that transfer liquids and gases in healthcare settings. Despite the Technical Committee’s desire to disrupt as little as possible surrounding the current practices with Luer connectors, ISO 80369-7 still makes many significant changes.


    Read More
  • 2024.01.03

    MasterControl Study: FDA, CPSC Recalls Up 115% Since 2018

    MasterControl , a provider of quality and manufacturing software solutions for the life sciences industry, has released a new study analyzing five years of product recall data from the Food and Drug Administration (FDA) and Consumer Product Safety Commission (CPSC) showing that recalls have increased more than 115 percent since 2018.


    Read More
  • 2023.11.28

    FDA Clarifies Recommendations on Cardinal Health Monoject Recall

    The new letter by FDA aimed to expand the recall notice to PCA pumps, which the original recall did not mention. It’s that gap in information that concerned FDA.


    Read More
X